The cholesterol-lowering effect of statins is modified by LILRB5 intolerance genotype: Results from a recruit-by-genotype clinical trial

Aleksi Tornio, Margherita Bigossi, Moneeza K. Siddiqui (Lead / Corresponding author), Gwen Kennedy, Alaa' Melhem, Mehul K. Chourasia, Cyrielle Maroteau, Roberto Pola, Daniel I. Chasman, Alexander S. F. Doney, Colin N. A. Palmer

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
48 Downloads (Pure)

Abstract

Background/Aims: Statin intolerance leads to poor adherence to statin therapy, resulting in a failure to achieve desired cholesterol reduction and adverse outcomes. The LILRB5 Asp247Gly genotype has been identified as being associated with statin intolerance and statin-induced myalgia. We conducted a randomized clinical trial to examine its role in immune response through T regulatory cell aggregation and in achieving cholesterol reduction targets.

Methods: A double-blind, cross-over, recruit-by-genotype trial was undertaken. A total of 18 participants who had either the Asp247Asp (T/T) genotype or the Gly247Gly (C/C) genotype were recruited to the study. Participants were randomised to receive placebo or atorvastatin 80 mg daily for 28 days. Following a washout period of 3 weeks, they were then switched to the opposite treatment. Biochemical and immunological measurements as well as interviews were performed prior to and after both treatment periods. Within genotype group comparisons were performed using repeated measures Wilcoxon tests. Two-way repeated measures ANOVA with genotype and treatment as factors were used to compare changes in biochemical parameters between groups during placebo and atorvastatin periods.

Results: Individuals with the Asp247Asp genotype had a greater increase in creatine kinase (CK) compared to those with Gly247Gly genotype in response to atorvastatin (p = 0.03). Those with Gly247Gly genotype had a mean non-HDL cholesterol reduction of 2.44 (95% CI:1.59 – 3.29) mmol/L while in Asp247Asp genotype group the mean reduction was 1.28 (95%CI: 0.48 – 2.07) mmol/L. The interaction between the genotype and atorvastatin treatment for total cholesterol (p = 0.007) and non-HDL cholesterol response was significant (p = 0.025). Immunological assessment showed no significant changes in aggregation of T regulatory cells by genotype.

Conclusion: The Asp247Gly variant in LILRB5, previously associated with statin intolerance, was associated with differential increases in creatine kinase and total cholesterol and non-HDL cholesterol-lowering response to atorvastatin. Taken together, these results suggest that this variant could have utility in precision cardiovascular therapy.

Original languageEnglish
Article number1090010
Number of pages7
JournalFrontiers in Pharmacology
Volume14
DOIs
Publication statusPublished - 14 Mar 2023

Keywords

  • ADR (adverse drug reaction)
  • RCT-randomized controlled trial
  • non-HDL cholesterol
  • statin (HMG-CoA reductase inhibitor)
  • treg-regulatory T cell

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint

Dive into the research topics of 'The cholesterol-lowering effect of statins is modified by LILRB5 intolerance genotype: Results from a recruit-by-genotype clinical trial'. Together they form a unique fingerprint.

Cite this